Alamar Biosciences has developed ARGO instruments that automate NULISA protein detection assays, creating a platform that drives recurring demand for consumables. This technology could expand the company's market beyond research into diagnostics through broader disease panels. Consumables sales are growing faster than instruments, signaling potential for long-term growth as the installed base expands. However, the company's high valuation and upcoming lock-up expiry lead to a cautious, neutral stance on its shares despite an IPO that supports commercial growth with reduced dilution risk.
Virgin Galactic's stock rating was upgraded from Sell to Hold due to a better outlook, though significant risks persist. Management expects positive quarterly cash flow by 2027, but concerns about stock dilution and high short interest continue. The ...
The Nicholas Crypto Income ETF (BLOX) provides a high 36% yield with weekly distributions, targeting investors focused on income who can tolerate high risk. BLOX uses synthetic crypto exposure and diversified holdings to reduce volatility and enhance...
Binance has launched a new four-week campaign offering a total of one million XRP tokens as rewards to holders of Ripple USD (RLUSD) on its platform. To qualify, users must hold at least 0.01 RLUSD and maintain an average daily derivatives trading vo...
Fred Piard's analysis finds healthcare equipment stocks undervalued compared to historical averages, while healthcare providers are valued near their baseline and pharmaceutical/biotech stocks appear moderately overvalued. The iShares U.S. Healthcare...
Investor Bill Ackman is increasing his stakes in Netflix, Visa, Mastercard, and S&P Global, focusing on companies with strong competitive advantages and attractive valuations. Netflix is seen as the clear winner in streaming with a growing global sub...
